124498-15-3

Basic information

• Product Name: 3-BROMO-5-(CHLOROMETHYL)ISOXAZOLE
• Synonyms: 3-BROMO-5-(CHLOROMETHYL)ISOXAZOLE;3-broMo-5-(chloroMethyl)-1,2-oxazole
• CAS NO: 124498-15-3
• Molecular Formula: C4H3BrClNO
• Molecular Weight: 196.43
• Product Categories: Methyl Halides;Oxazoles, Isoxazoles & Benzoxazoles;Methyl Halides;Oxazoles, Isoxazoles & Benzoxazoles
• Mol File: 124498-15-3.mol

Chemical Properties

• Boiling Point: 277.2 °C at 760 mmHg
• Flash Point: 121.5 °C
• Appearance: /
• Density: 1.796 g/cm³
• Vapor Pressure: 0.00772mmHg at 25°C
• Refractive Index: 1.536
• CAS DataBase Reference: 3-BROMO-5-(CHLOROMETHYL)ISOXAZOLE(CAS DataBase Reference)
• NIST Chemistry Reference: 3-BROMO-5-(CHLOROMETHYL)ISOXAZOLE(124498-15-3)
• EPA Substance Registry System: 3-BROMO-5-(CHLOROMETHYL)ISOXAZOLE(124498-15-3)

Safety Data

• Hazard Codes: Xi
• Hazardous Substances Data: 124498-15-3(Hazardous Substances Data)

Usage

Uses

Used in Medicinal Chemistry:
3-Bromo-5-(chloromethyl)isoxazole is used as a building block for the synthesis of pharmaceuticals, given its unique bromine and chloromethane substituents. These features allow it to be a versatile component in the creation of new therapeutic agents.
Used in Pharmaceutical Synthesis:
In the pharmaceutical industry, 3-bromo-5-(chloromethyl)isoxazole is used as a key intermediate in the development of new drugs. Its chemical structure contributes to the formation of various medicinal compounds that can be used to treat a wide array of diseases.
Used in Research and Development:
3-Bromo-5-(chloromethyl)isoxazole is utilized in research settings to explore its potential as a precursor in the synthesis of novel compounds with potential therapeutic applications. Its reactivity and structural properties make it a valuable tool in the ongoing quest for new medicines.
Safety Measures:
It is important to handle 3-bromo-5-(chloromethyl)isoxazole with appropriate safety measures due to its synthetic nature and potential health hazards. Detailed information on its properties, such as molecular weight, boiling point, and density, can be found on chemical databases to ensure proper handling and usage.

InChI:InChI=1/C4H3BrClNO/c5-4-1-3(2-6)8-7-4/h1H,2H2

Upstream product

• 78-88-6 2,3-Dichloroprop-1-ene 
• 74213-24-4 N-dibromomethylidenehydroxylamine 
• 624-65-7 2-propynyl chloride 

Downstream Products

• 2763-93-1 5-Aminomethyl-3-bromoisoxazole 

Relevant articles and documents

An improved synthesis of muscimol

A regiospecific 1,3-dipolar cycloaddition/elimination is the key-step of a convenient, gram-scale synthesis of the GABA-agonist muscimol (1).

Synthesis and pharmacological profile of a series of 2,5-substituted-N,N-dimethyltryptamine derivatives as novel antagonists for the vascular 5-HT1B-like receptor

The coronary 5-HT1B-like receptor has been implicated in vasospasm and it is postulated that a 5-HT1B-like antagonist may block the detrimental action of 5-HT whilst not interfering with normal blood vessel function. The synthesis and pharmacological profile of a novel series of 2-(N-heteroaryl)carboxamido-5-substituted-N,N-dimethyltryptamine derivatives as silent (as judged by the inability of angiotensin II to unmask 5-HT1B-like receptor mediated agonist activity in the rabbit femoral artery), competitive and selective 5-HT1B-like receptor antagonists is described. Modifications to the 2-carboxamido sidechain as well as the 5-ethylene linked heterocycle are explored. N-Furfuryl-5-[2-(N-phthalimido)ethyl]-3-[2-(dimethylamino)ethyl]-1H-indole-2- carboxamide (34) was discovered which fulfilled our in vitro selection criteria and which had a favourable pharmacokinetic profile. Compound 34 showed good affinity (pKB = 7.38) for the vascular 5-HT1B-like receptor and greater than 125 fold selectivity over α1-adrenoceptor affinity. The selectivity of 34 and related compounds for the 5-HT1B-like receptor over other receptor subtypes is discussed and a mode of binding for this class of compound to a pharmacophore model is proposed. The Royal Society of Chemistry 1999.

Synthesis and pharmacological investigation of cholinergic ligands structurally related to muscarone

Five new analogs of muscarone were synthesized in order to evulate the influence of the carbonyl group on muscarinic activity.We chose to introduce structural variations at the C-2 and C-3 positions of the tetrahydrofuran ring.The muscarinic activity was evaluated in vitro on guinea pig atria and ileum as well as on rat jejunum and urinary bladder.All the new derivatives are less potent than muscarone and three of them displayed a potency very close to that previously reported for muscarine.The tissue selectivity observed for the 3-methylene derivative which is eight times more potent on guinea pig ileum than atria is worth noting.The present data show the lack of a simple relationship between the polarity of the group located in the 3-position of the ring and the muscarinic activity.

PHARMACOLOGICALLY ACTIVE GUANIDINE COMPOUNDS

The compounds are substituted thioalkyl-, aminoalkyl-and oxyalkyl-guanidines which are inhibitors of histamine activity.

PHARMACOLOGICALLY ACTIVE THIOUREA AND UREA COMPOUNDS

The compounds are substituted thioalkyl-, aminoalkyl-and oxyalkyl-thioureas and ureas which are inhibitors of histamine activity.